Generic strategic alliances

7 December 2011

The generic drugs sector’s role as the provider of affordable drugs has widely benefitted public and private health payers keen to control costs. But in the current economic climate, downward pressure on prices is impacting the generic sector, with increases in acquisition and strategic partnering now firmly part of the competitive landscape.

According to a new Espicom Business Intelligence report, titled Generic Drugs: Global Collaboration Opportunities, branded and generic companies should consider greater partnering as part of their current strategy and identifies 160 generic drugs manufacturers worldwide as key targets.

The report analyses a wide variety of generic companies located in 35 countries, from specialist players concentrating on specific therapies to broadly based providers active in many markets. The size and value of the companies is broad, too, with among the largest being Hypermarcas in Brazil and R-Pharm in Russia.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics